{"groups":[{"description":"subjects with relapsed/refractory MCL","id":"FG000","title":"ACP-196 100 mg BID"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"59"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"51"}],"type":"study terminated by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"SITE CLOSURE - PI RETIREMENT"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"124"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"124"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"For the ACE-LY-004 program, Study Terminated by Sponsor refers to the following: Patients receiving treatment benefits will continue to be provided with study medication in the Post Final Analysis Management of the trial. No further data collection for analysis and reporting will be completed after the final Analysis."}